Boston Scientific has secured $7.25 billion in new debt to fund its planned acquisition of Penumbra. The company priced $3.0 billion in U.S. dollar senior notes and €4.25 billion in euro senior notes on November 19, 2026. The offerings are set to close on December 1, 2026, and are not contingent on the Penumbra deal's completion.
The notes will mature between 2029 and 2046 for the euro-denominated debt and between 2029 and 2036 for the dollar-denominated debt. If the Penumbra acquisition fails to close by the applicable deadline, the dollar and euro notes, excluding the floating-rate notes, will be subject to special mandatory redemption at 101% of principal plus accrued interest.
The proceeds from these offerings will be used to finance the Penumbra acquisition and cover related fees and expenses. The underwriting agreements for both the dollar and euro notes were signed on November 19, 2026.